Share page on LinkedIn
  1. Home
  2. News & Events
  3. Events
  4. Industry events
  5. Financial Times Global Pharma and Biotech Summit 2023

Financial Times Global Pharma and Biotech Summit

7-9 November 2023, digital and in-person event

Driving life sciences innovation in a disrupted world

The world of life sciences is in a period of relentless disruption. Advances in technology are transforming research and development. Innovative treatments such as mRNA vaccines and cell therapies are reshaping healthcare as we know it. Meanwhile, companies face the challenge of bringing products to market in an unsettled regulatory environment.

The FT Global Pharma and Biotech Summit brings together industry leaders and experts to share insights and perspectives on what’s new in areas such as drug discovery, clinical trials, market access and patient engagement. 

ICON speakers:

George A. McMillan

Chief Commercial Officer

Wednesday, November 8, 11:45 AM - 12:05 PM GMT

Fireside Chat: Partnering for progress - Best practices to drive efficiency and effectiveness in drug development

CROs continue to become more integrated as they develop and implement new technologies and operational models that make development cycles more efficient and effective. This session will explore the current environment for partnerships and examine best practices to leverage combined knowledge and accelerate progress, including developing bespoke partnership operating models, ensuring cultural alignment between organisations, and establishing effective change management strategies and communication plans.

Ashmee Bharadia

Vice President, Patient Recruitment & Retention

Wednesday, November 8, 12:05 PM - 12:45 PM GMT

Panel: How is Patient Engagement Evolving Clinically and Commercially?

From clinical trials to consultations, technology is transforming patient engagement across health systems. As new products are developed and market conditions evolve, pharma companies are changing how they connect with patients on every level. 

  • How is patient engagement evolving with the technological transformation of clinical development?
  • What are some of the barriers to patient engagement that exist in different health systems? 
  • How can companies engage with patients online without running foul of advertising restrictions?
  • Why are regulators and HTA bodies demanding the patient voice play a larger role in drug development?
  • How can insights gained from patient engagement be fed back into business models?

Richard Torbett, Chief Executive, Association of the British Pharmaceutical Industry

Véronique Walsh, General Manager and Vice President, UK and Ireland, Gilead Sciences

Hanno Ronte, Partner, Deloitte

Other featured speakers include:

  • Shreeram Aradhye, President, Global Drug Development and Chief Medical Officer, Novartis
  • Amalia Adler-Waxman, Senior Vice President, Global Head of ESG and Head of Corporate Affairs, International Markets, Teva Pharmaceuticals
  • Renée Aguiar-Lucander, CEO, Calliditas Therapeutics
  • Rohit Alimchandani, Head of Life Sciences, UK and Ireland, Cognizant
  • Stéphane Bancel, CEO, Moderna
  • Warner Biddle, Global Head of Commercial, Kite Pharma
  • Jean-Jacques Bienaimé, Chairman and CEO, BioMarin Pharmaceutical
  • Tim Broke-Smith, Vice President, Global Pharma Partnerships, Huma Therapeutics
  • Kylie Bromley, Vice President and Managing Director, UK and Ireland, Biogen
  • Sean Breen, Head of Public-Private Partnerships and Global Science Policy, Takeda
  • Roel Bulthuis, Managing Partner, Syncona Investment Management Limited
  • Fernando Campo, Associate Vice President, Diabetes, Lilly Northern Europe
  • Emma Charles, Senior Vice President, Intercontinental Markets, Bristol Myers Squibb
  • Ivan Clement, Global Associate Director, RWE and Innovative Evidence in Neuroscience, Novartis
  • Werngard Czechtizky, Head of Medicinal Chemistry, Respiratory and Immunology, AstraZeneca
  • Eric Dube, President and CEO, Travere Therapeutics
  • Juergen Eckhardt, Head of Licensing and Open Innovation, Member of the Executive Committee, Bayer Pharmaceuticals
  • Marie-Andrée Gamache, Country President, Novartis UK and Ireland
  • Yvonne Greenstreet, CEO, Alnylam Pharmaceuticals
  • Liz Hampson, Executive Director, Europe, Deloitte Health Equity Institute
  • Mark Hicken, Vice President of Strategy for EMEA, Johnson & Johnson Innovative Medicine
  • Paul Hudson, CEO, Sanofi
  • Julia Hoover, General Manager, UK and Ireland, Ferring Pharmaceuticals
  • Jayasree K. Iyer, CEO, Access to Medicine Foundation
  • Avak Kahvejian, General Partner, Flagship Pioneering
  • Matthew B. Klein, resident and CEO, PTC Therapeutics
  • Michael Lewis, Professor of Life Science Innovation, University of Birmingham
  • Henriette Lonkvist, Global Head of Customer Relationship Management, Ferring Pharmaceuticals
  • Stacy Malueg, Head of Supply Chain, US, Genentech
  • Ricardo Marek, President, Europe and Canada Business Unit, Takeda
  • Alan McDougall, Senior Vice President and Head of Medical Affairs, Europe and Canada, Astellas Pharma Europe
  • Andrew Miniuks, ead of Access Strategy and Pricing, Bristol Myers Squibb
  • Seyda Atadan Memis, General Manager, UK and Ireland, Takeda
  • Nathalie Moll, Director General, European Federation of Pharmaceutical Industries and Associations (EFPIA)
  • Rohit Nambisan, CEO, Lokavant
  • Samantha Pearce, Senior Vice President, Europe and International, Jazz Pharmaceuticals
  • June Raine, CEO, Medicines and Healthcare products Regulatory Agency (MHRA)
  • Ryan Richardson, Chief Strategy Officer, BioNTech
  • Sam Roberts, Chief Executive, National Institute for Health and Care Excellence (NICE)
  • Fred Roeder, Managing Director, Consumer Choice Center
  • Dominik Ruettinger, Global Head of Research and Early Development, Oncology, Bayer Pharmaceuticals
  • Pinder Sahota, General Manager and Corporate Vice President, United Kingdom, Novo Nordisk
  • Kimberly Smith, Senior Vice President, Head of Research and Development, ViiV Healthcare
  • Clare Terlouw, Head of Ventures, LifeArc
  • Jean-Christophe Tellier, CEO, UCB
  • Shruti Vasudev, Head of Transformation and Change Enablement, Merck Life Science
  • Erica Whittaker, Vice President and Head of UCB Ventures, UCB
  • Jacky Vonderscher, CEO, ENYO Pharma
  • Jan G. J. van de Winkel, President and CEO, Genmab
  • Matthew Winterman, SVP of Global Supply Chain and Strategy, AstraZeneca